Head-To-Head Comparison: Nexentis Technologies (NASDAQ:NXTS) and Theravance Biopharma (NASDAQ:TBPH)

Theravance Biopharma (NASDAQ:TBPH) and Nexentis Technologies (NASDAQ:NXTS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

Insider and Institutional Ownership

99.1% of Theravance Biopharma shares are owned by institutional investors. Comparatively, 61.2% of Nexentis Technologies shares are owned by institutional investors. 7.6% of Theravance Biopharma shares are owned by company insiders. Comparatively, 6.5% of Nexentis Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations for Theravance Biopharma and Nexentis Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0	7	0	0	2.00
Nexentis Technologies	1	0	0	0	1.00

Theravance Biopharma currently has a consensus target price of $19.00, indicating a potential upside of 11.57%. Given Theravance Biopharma’s stronger consensus rating and higher possible upside, equities analysts clearly believe Theravance Biopharma is more favorable than Nexentis Technologies.

Earnings and Valuation

This table compares Theravance Biopharma and Nexentis Technologies”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$104.31 million	8.48	$105.89 million	$1.01	16.86
Nexentis Technologies	$210,000.00	3.55	-$4.00 million	($96.07)	-0.01

Theravance Biopharma has higher revenue and earnings than Nexentis Technologies. Nexentis Technologies is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Theravance Biopharma and Nexentis Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	51.58%	-0.77%	-0.46%
Nexentis Technologies	N/A	-304.79%	-178.91%

Risk and Volatility

Theravance Biopharma has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500. Comparatively, Nexentis Technologies has a beta of 1.95, indicating that its stock price is 95% more volatile than the S&P 500.

Summary

Theravance Biopharma beats Nexentis Technologies on 12 of the 13 factors compared between the two stocks.

About Theravance Biopharma

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs.
Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY.
For more information, please visit www.theravance.com.

About Nexentis Technologies

N2OFF, Inc., an agri-food tech company, engages in the development and sale of eco-friendly green solutions for the food industry to enhance food safety and shelf life of fresh produce. Its products are based on proprietary blend of food acids combined with various oxidizing agent-based sanitizers and low concentrated fungicides for cleaning, sanitizing, and controlling pathogens on fresh produce that are safer for human consumption and extend their shelf life by reducing their decay. The company’s products include SavePROTECT or PeroStar, a processing aid for post-harvest application that is added to fruit and vegetable wash water; and SF3HS and SF3H, a post-harvest cleaning and sanitizing solution to control plant and foodborne pathogens. It also offers SpuDefender for controlling post-harvest potato sprouts; and FreshProtect to control spoilage-creating microorganisms on post-harvest citrus fruit. The company was formerly known as Save Foods, Inc. and changed its name to N2OFF, Inc. in March 2024. N2OFF, Inc. was incorporated in 2009 and is headquartered in Hod HaSharon, Israel.